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Abstract 
Pneumotoxic drugs like amiodarone and m-TOR inhibitors (m-TORi) may be administered 
contemporaneously in therapy for patients who had renal transplants. We present a case of 
amiodarone pulmonary toxicity (APT) in a patient treated with amiodarone and everolimus. A 
57-year-old Caucasian male, under treatment with both everolimus (for 3 years) and 
amiodarone (for 2 months), presented with fever, dyspnoea and a negative chest X-ray after 
his second kidney transplant with suboptimal serum creatinine (3 mg/dl). A non-contrastive 
high-resolution CT scan showed bilateral interstitial lung disease with an associated 
reduction in carbon monoxide diffusing capacity. Bronchoalveolar lavage (BAL) was negative 
for an infection, but BAL cytology was suitable for APT (50% of ‘foamy’ macrophages). A 
complete recovery was achieved after amiodarone interruption and an oral steroid therapy 
increase. Everolimus was continued. His kidney function remained unchanged in the 
upcoming months. In conclusion, we suggest a possible synergistic effect between m-TORi 
and amiodarone. Furthermore, we propose a diagnostic algorithm that can be used as a 
surveillance tool to identify a potential initial lung damage in patients treated with 1 or more 
pneumotoxic drugs. © 2014 S. Karger AG, Basel 
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Introduction 
Amiodarone, a benzofuran derivative, is one of the most widely used anti-arrhythmic 
agents in renal transplant patients [1]. Unfortunately, despite its undoubted effectiveness, 
amiodarone has many side effects, including corneal micro deposits, optic neuropathy 
and/or optic neuritis, photosensitivity, blue-gray pigmentation, hypo- and hyperthyroidism, 
hepatic disorders, and amiodarone pulmonary toxicity (APT) [2]. 
APT occurs in approximately 5% of treated patients and represents the most serious 
and life-threatening side effects (mortality ranges from 9% in chronic pneumonia to 50% in 
patients who develop acute respiratory distress syndrome) [3]. 
Several other drugs can be responsible for pulmonary toxicity. The inhibitors of the 
mammalian target of rapamycin (mTORi) were approved in 1999 as immunosuppressants 
for the use in transplants. Since 2000, some cases of non-infectious pneumonitis have been 
reported in solid organ transplants in which the patients were treated with mTORi [4]. 
Herein, we present a case of APT in a renal transplant recipient treated with amiodarone 
and everolimus. 
Case Report 
A 57-year-old Caucasian male with end-stage renal disease, secondary to chronic glo-
merulonephritis (not biopsy proven, but suggested by the evidence of a nephrotic range 
proteinuria), received a second renal transplant in our center in January 2004. He was 
initially treated with tacrolimus (Prograf®, Astellas Pharma), steroids, mycophenolate 
mofetil (CellCept®, Roche), and then replaced by everolimus (Certican®, Novartis Pharma) in 
2008 after a biopsy demonstrated chronic allograft nephropathy and severe arteriosclerosis. 
The patient’s medical history included chronic microcytic hypochromic anemia (hemo-
globin 10–10.4 g/dl), hepatitis C viremia, mild hypertension, hyperlipidemia with intoler-
ance to statin therapy with myalgia and creatine phosphokinase increase. 
In October 2011, amiodarone (initial dose 600 mg/day, maintenance dose 200 mg/day), 
and warfarin were started because of a paroxysmal atrial fibrillation. At this time, echocardi-
ography showed a normal ejective fraction (65%) with a moderate left ventricular hypertro-
phy and a severe left atrial dilation (estimated volume 180 ml) with no valvular diseases. 
In December 2011, he presented with malaise, shortness of breath, fever, dyspnoea with 
minimal effort and worsening of renal function (serum creatinine up to 4.3 mg/dl). 
On presentation, he was afebrile with normal blood pressure and oxygen saturation. 
Arterial blood pressure was 123/72 mm Hg. The physical examination was notable only for 
decreased breathing sounds, but without any chest X-ray alteration. The blood tests showed 
an isolated increase of C-reactive protein (155 mg/l) with a normal white blood cell count. 
Hemoglobin, cholesterol, and triglycerides were unchanged (9.8 g/dl, 272 and 153 mg/dl, 
respectively). Daily immunosuppressive therapy on admission included low-dosage 
tacrolimus (3 mg/day with target levels 2–3 ng/ml), everolimus (1.75 mg/day with target 
levels 5–6 ng/ml), and prednisone (5 mg/day). Other medication was irbesartan, doxazosin, 
amlodipine, metoprolol, omeprazole, furosemide, allopurinol, long-chain omega-3 fatty 
acids, magnesium pidolate, ferrous liposomes, warfarin, and amiodarone. 
Early in hospitalization, the patient became febrile and his respiratory symptoms be-
came relevant. No improvement was noted in spite of his antibiotic treatment (ceftriaxone, 
piperacillin-tazobactam and doxycycline). On day 10, a high-resolution CT scan (HRCT) of 
the chest showed a scattered, bilateral, interstitial lung disease. Neither clinical nor 
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radiological signs of pulmonary oedema were present. Everolimus levels were within the 
normal range. No fluid overload was noted, so the dose of diuretics was not increased, and 
urine output was unchanged. The echocardiographic pattern was unmodified. Pulmonary 
function tests (PFTs) revealed moderate air trapping and decreased values of carbon 
monoxide diffusing capacity (DLCO). 
A bronchoscopy with bronchoalveolar lavage (BAL) was performed on day 15. During 
the procedure, no macroscopic alteration and/or sign of pulmonary oedema was noted. BAL 
did not identify any bacterial, fungal or viral organisms, but BAL cytology detected ‘foamy’ 
macrophages (50% of macrophages counted with a normal total cell count). On day 17, 
amiodarone was stopped, and oral steroid therapy was increased from 5 to 12.5 mg/day. 
Everolimus was maintained with careful level monitoring. Gradually, his pulmonary and 
clinical status improved, the patient became afebrile, and renal function improved. 
On day 30, the patient was discharged. In March 2012, PFTs showed an improvement in 
DLCO and the steroid dose was reduced from 12.5 to 7.5 mg/day. A further reduction to 5 
mg was initiated in April when HRTC was repeated and demonstrated a complete disap-
pearance of the bilateral interstitial disease. 
After his discharge, the pulmonary symptoms were absent. The patient’s renal function 
was unchanged (serum creatinine between 3 and 3.5 mg/dl), maintaining the same 
immunosuppressive therapy with everolimus, low-dose tacrolimus and steroids. 
Discussion 
Amiodarone, because of its high level of effectiveness, is used worldwide, notwithstand-
ing amiodarone-related adverse effects. APT, the most serious and life threatening complica-
tion, occurs in 5–10% of patients [3]. 
APT may also sporadically start at the beginning of therapy, even after its withdrawal, 
without a threshold dose, but it has been commonly described in patients treated with an 
amiodarone dose between 300 and 800 mg/day. Doses greater than 400 mg/day should be 
avoided. The onset of pulmonary toxicity may either be insidious or rapidly progressive, 
with a wide range of clinical presentations, which include acute lung injury (from fibrinous 
organising pneumonia to acute respiratory distress syndrome) and subacute/chronic 
patterns (chronic organising pneumonia, lung fibrosis). Pleural/pericardial involvement can 
be observed. 
Three different mechanisms of lung toxicity have been suggested: cytotoxic, angioten-
sin-related and immune-mediated lung toxicity [5] (fig. 1). 
Clinical symptoms like cough, shortness of breath, dyspnoea, new chest infiltrates in 
imaging studies, and a reduction in DLCO are the cardinal elements for a diagnosis; a 
meticulous exclusion of infection, malignancy and pulmonary oedema has to be made first 
[6]. 
In this context, BAL has a key role, providing evidence of APT (with ‘foamy’ macrophag-
es on cytology). However, in mTORi patients, BAL could also help diagnosing mTORi lung 
toxicity by demonstrating a different pattern of cytology (lymphocytic or eosinophilic 
alveolitis). The role of a lung biopsy is under debate, but at the present time, lung biopsy is 
considered only when the aforementioned tests are inconclusive. The histological pattern is 
normally characterized by intra-alveolar foamy macrophages in APT [7] and by a lymphocyt-
ic interstitial infiltrate in mTORi lung toxicity [8, 9]. 
In our case, some data are unusual. The symptoms of pulmonary disfunction were rele-
vant, despite a scattered interstitial lung disease. The oral amiodarone initial dose was low, 
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as well as the maintenance regimen dose; moreover, well-known risk factors (older age, pre-
existing lung disease or a history of cardiothoracic surgery) were absent [10]. Besides, the 
patient had long been treated with angiotensin converting enzyme inhibitors (albeit 
withdrawn 1 month before hospitalisation) and angiotensin receptor blockers, which are the 
only 2 drugs that may have a somewhat ‘protective role’ towards APT [11]. 
In the authors’ opinion, a synergistic effect between mTORi and amiodarone could be 
hypothesised. We suggest a possible connection between m-TORi pulmonary toxicity and 
APT (fig. 2). 
It has been postulated that lysosomal phospolipid accumulation, causing a formation of 
‘foamy’ macrophages (first step in the APT causative mechanism) [7], results in lysosomal 
disfunction with an increasing autophagy. Activation of the mTORC1 complex is known to 
reduce autophagy and, hence, the immunosuppressive drugs are able to inhibit the mTOR 
complex and could controversely produce a worsening of the pulmonary amiodarone side 
effects by increasing lysosomal-induced autophagy [12]. In our opinion, this mechanism, first 
reported in a patient treated with sirolimus and pentamidine [13], could also possibly occur 
when other drugs – able to induce phospholipid accumulation (such as amiodarone) and 
mTORi – are prescribed together, facilitating the development of APT. The mutual situation 
is not applicable because m-TORi pulmonary toxicity seems to be triggered by a different 
stimulus and has a different immunological pathway [8]. 
To the best of our knowledge, 2 cases of interstitial pneumonia in transplanted patients, 
treated with an mTORi (sirolimus and everolimus, respectively) and amiodarone, have been 
reported [14, 15]. In both papers, patients ceased both amiodarone and mTORi in a 
condition of pulmonary interstitial damage, with a suspected cumulative toxicity (patient No. 
2 in Haydar et al.’s [14] paper and patient No. 2 in Otton et al.’s [15] paper). This issue is not 
commented on in the paper by Otton et al. [15], while Haydar et al. [14] suggested the 
hypothesis of a potential synergistic effect. Besides, when everolimus was resumed [15], 
pneumonia relapsed, too. There is no mention of amiodarone reintroduction. In the case 
described by Haydar et al. [14], neither amiodarone nor sirolimus were restarted, but during 
the development of interstitial pneumonitis BAL, the cytology was characterized by an 
abundance of lymphocytes. Based on these data, one could assume lung damage to be 
mTORi-induced in both cases.  
In our patient, on the contrary, we indicate amiodarone toxicity as the culprit of the 
interstitial pneumonia (in a patient also taking everolimus). After amiodarone withdrawal, 
lung pathology regressed while everolimus therapy continued. To the best of our knowledge, 
this is the first case reported in the literature. We are aware that this synergistic toxicity is 
not demonstrated in this single case, but it is deducible based on the literature data 
regarding the mechanism of damage caused by the 2 drugs. 
According to our experience, as a first step, we suggest that amiodarone is first pre-
scribed for a patient who is taking m-TORi or vice versa. PFTs, DLCO tests, chest X-rays, and 
non-invasive lung screening tests are performed as baseline treatments. In case of initial 
symptoms of lung disease, an in-depth analysis (HRCT, BAL) should be promptly performed. 
After the diagnosis of drug pulmonary toxicity, treatment is composed by: drug interruption, 
steroid treatment, repetition of PFTs after 1 month, and HRCT after 2 months. Steroid dose 
and treatment duration are very individual and based on the severity of the disease and the 
patients’ comorbities; as a first line treatment, steroids are used at a 0.8–1 mg/kg dose for 3–
4 weeks, with tapering doses of 10 mg/day. 
Moreover and as a second step, we propose a diagnostic algorithm which is used as a 
surveillance tool and is able to predict initial lung damage in a patient treated with mTORi 
and/or other pneumotoxic drugs (fig. 3). 
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As described in figure 3, a DLCO test could be performed before starting the potential 
pneumotoxic drug and repeated 6 months after. If the difference between the 2 tests is 
greater than 10%, we suggest performing HRTC, even in case of an interstitial pneumonitis 
diagnosis (BAL). Otherwise, DLCO should be repeated after 6 months. With a difference 
between 5 and 10% on DLCO, a further evaluation should be planned after 1 month; with a 
less than 5% difference, we suggest repeating the DLCO test after 6 months. 
In conclusion, in patients with a fragile hemodynamic and immunological balance as 
renal transplant recipients, the contemporary use of pneumotoxic drugs requires careful 
monitoring and thorough follow-up in view of a possible synergistic mechanism in lung 
toxicity. 
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Fig. 1. Amiodarone mechanisms of lung toxicity. AEC = Alveolar epithelial cells; Th1 = T helper type 1 
lymphocyte; Th2 = T helper type 2 lymphocyte; TNF-α = tumour necrosis factor-α; TGF-β = transforming 
growth factor-β. 
 
 
 
Fig. 2. Scheme for a hypothetical synergistic effect between m-TORi and amiodarone in lung toxicity. 
Promoting effect: white arrows; inhibiting effect: black arrows. 
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Fig. 3. Surveillance algorithm. △ = difference (in %) between the last 2 DLCO tests. 
 
